MX358463B - Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa. - Google Patents

Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa.

Info

Publication number
MX358463B
MX358463B MX2014002031A MX2014002031A MX358463B MX 358463 B MX358463 B MX 358463B MX 2014002031 A MX2014002031 A MX 2014002031A MX 2014002031 A MX2014002031 A MX 2014002031A MX 358463 B MX358463 B MX 358463B
Authority
MX
Mexico
Prior art keywords
pyrano
thiazole
glycosidase inhibitors
inhibitors
glycosidase
Prior art date
Application number
MX2014002031A
Other languages
English (en)
Other versions
MX2014002031A (es
Inventor
Liu-Bujalski Lesley
Goutopoulos Andreas
Qui Hui
Yu Henry
Donnelly Marianne
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2014002031A publication Critical patent/MX2014002031A/es
Publication of MX358463B publication Critical patent/MX358463B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nuevos compuestos de la fórmula (I), en donde R1 a R4 y X tienen el significado de acuerdo a las reivindicaciones, son inhibidores de glucosidasa, y se pueden emplear, inter alia, para el tratamiento de la enfermedad de Alzheimer.
MX2014002031A 2011-08-25 2012-08-22 Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa. MX358463B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527323P 2011-08-25 2011-08-25
PCT/US2012/051785 WO2013028715A1 (en) 2011-08-25 2012-08-22 Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors

Publications (2)

Publication Number Publication Date
MX2014002031A MX2014002031A (es) 2014-03-21
MX358463B true MX358463B (es) 2018-08-22

Family

ID=46759099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002031A MX358463B (es) 2011-08-25 2012-08-22 Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa.

Country Status (21)

Country Link
US (2) US8884023B2 (es)
EP (1) EP2748171B1 (es)
JP (1) JP5893738B2 (es)
KR (1) KR102008032B1 (es)
CN (1) CN103930428B (es)
AU (1) AU2012298949B2 (es)
BR (1) BR112014004219B1 (es)
CA (1) CA2845149C (es)
DK (1) DK2748171T3 (es)
EA (1) EA022562B1 (es)
ES (1) ES2568603T3 (es)
HR (1) HRP20160334T1 (es)
HU (1) HUE029390T2 (es)
IL (1) IL231008A (es)
MX (1) MX358463B (es)
PL (1) PL2748171T3 (es)
RS (1) RS54773B1 (es)
SG (1) SG2014009617A (es)
SI (1) SI2748171T1 (es)
WO (1) WO2013028715A1 (es)
ZA (1) ZA201400387B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201249848A (en) 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
LT2655388T (lt) 2010-12-23 2016-11-10 Alectos Therapeutics Inc. Selektyvieji glikozidazės inhibitoriai ir jų panaudojimas
US8927507B2 (en) 2011-03-24 2015-01-06 Ernest J. McEachern Selective glycosidase inhibitors and uses thereof
US9718854B2 (en) * 2011-03-31 2017-08-01 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9701693B2 (en) 2011-06-27 2017-07-11 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000084A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9199949B2 (en) 2011-06-27 2015-12-01 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
HRP20160334T1 (hr) * 2011-08-25 2016-05-06 Merck Patent Gmbh Pirano [3, 2 - d][1, 3]tiazol kao inhibitori glikozidaze
WO2014032185A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032188A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
CA2890115A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
BR112017003658B1 (pt) 2014-08-28 2022-12-06 Asceneuron Sa Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica
US10571963B2 (en) * 2015-09-18 2020-02-25 Toray Industries, Inc. Housing
EP3419976B1 (en) 2016-02-25 2021-04-07 Asceneuron SA Acid addition salts of piperazine derivatives
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
AU2017222964B2 (en) 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
EP3585783A2 (en) 2016-02-25 2020-01-01 Asceneuron SA Sulfoximine glycosidase inhibitors
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
EP3841093B1 (en) 2018-08-22 2023-06-21 Asceneuron SA Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
US12565504B2 (en) * 2019-10-29 2026-03-03 Biogen Ma Inc. Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436687A1 (en) * 2005-03-01 2012-04-04 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
DE602007002792D1 (de) * 2006-01-30 2009-11-26 Irm Llc Verbindungen und zusammensetzungen als ppar-modulatoren
EP2057171A4 (en) * 2006-08-31 2010-04-21 Univ Fraser Simon SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF
CN107253970A (zh) * 2006-08-31 2017-10-17 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US8933040B2 (en) 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof
LT2655388T (lt) 2010-12-23 2016-11-10 Alectos Therapeutics Inc. Selektyvieji glikozidazės inhibitoriai ir jų panaudojimas
HRP20160334T1 (hr) * 2011-08-25 2016-05-06 Merck Patent Gmbh Pirano [3, 2 - d][1, 3]tiazol kao inhibitori glikozidaze

Also Published As

Publication number Publication date
HRP20160334T1 (hr) 2016-05-06
HUE029390T2 (en) 2017-02-28
MX2014002031A (es) 2014-03-21
IL231008A0 (en) 2014-03-31
AU2012298949B2 (en) 2016-09-22
EP2748171B1 (en) 2016-02-03
IL231008A (en) 2016-04-21
CA2845149A1 (en) 2013-02-28
SI2748171T1 (sl) 2016-06-30
EA022562B1 (ru) 2016-01-29
EA201490493A1 (ru) 2014-06-30
KR102008032B1 (ko) 2019-08-06
CN103930428B (zh) 2016-05-11
BR112014004219A2 (pt) 2017-03-14
RS54773B1 (sr) 2016-10-31
BR112014004219B1 (pt) 2021-11-30
AU2012298949A1 (en) 2014-01-30
JP5893738B2 (ja) 2016-03-23
CA2845149C (en) 2019-12-31
KR20140054007A (ko) 2014-05-08
WO2013028715A1 (en) 2013-02-28
US9469657B2 (en) 2016-10-18
SG2014009617A (en) 2014-05-29
DK2748171T3 (en) 2016-05-09
US20150018318A1 (en) 2015-01-15
EP2748171A1 (en) 2014-07-02
CN103930428A (zh) 2014-07-16
HK1196607A1 (zh) 2014-12-19
PL2748171T3 (pl) 2016-06-30
ZA201400387B (en) 2015-05-27
ES2568603T3 (es) 2016-05-03
US8884023B2 (en) 2014-11-11
JP2014527060A (ja) 2014-10-09
US20140243370A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
MX2014002031A (es) Pirano[3,2-d][1,3]tiazol como inhibidores de glicosidasa.
NZ601121A (en) 5-alkynyl-pyrimidines
MX351812B (es) Derivados de piridona.
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
MX336381B (es) Boronatos como inhibidores de arginasa.
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
MX339992B (es) Piridin-2-amidas utiles como agonistas canabinoides 2 (cb2).
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
PH12015501083B1 (en) Novel pyridine derivatives
MY171831A (en) Novel fused pyrimidine compound or salt thereof
PH12013500694A1 (en) Process for manufacturing dihydropteridinones and intermediates thereof
MX349373B (es) Nuevos derivados de pirazina.
MY157423A (en) Production method of intermediate compound for synthesizing medicament
MX2014008918A (es) Nuevos derivados de pirrolidina.
MX2013008256A (es) Derivados novedosos de tetrahidroquinolina.
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MX355654B (es) Derivado de paroxetina.
TN2011000530A1 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
IN2012DN06600A (es)
NZ724424A (en) Pyrimidine derivatives for the treatment of bacterial diseases
TN2013000075A1 (en) Production method of intermediate compound for synthesizing medicament
UA64492U (en) 3-METHYL-7-β-HYDROXY-γ-(N-CHLOROPHENOXY)PROPYL-8-(2'-BROMO-3'-PHENYL)ALLYLIDENEHYDRAZINOXANTHINE EXHIBITING DIURETIC ACTION
TN2011000049A1 (en) 5-alkynyl-pyrimidines

Legal Events

Date Code Title Description
FG Grant or registration